Psychiatry Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the psychiatry deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of psychiatry deals from 2019 to 2024.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of psychiatry dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in psychiatry dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the psychiatry field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in psychiatry dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of psychiatry deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of psychiatry deals listed by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in psychiatry deal making since 2019.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Psychiatry Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Fully revised and updated, the report provides details of psychiatry deals from 2019 to 2024.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of psychiatry dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in psychiatry dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the psychiatry field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in psychiatry dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of psychiatry deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of psychiatry deals listed by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in psychiatry deal making since 2019.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key Benefits
Psychiatry Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2019
- Browse psychiatry collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report Scope
Psychiatry Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of psychiatry trends and structure of deals entered into by leading biopharma companies worldwide.Psychiatry Collaboration and Licensing Deals includes:
- Trends in psychiatry dealmaking in the biopharma industry
- Overview of collaboration and licensing deal structure
- Directory of psychiatry deal records covering pharmaceutical and biotechnology
- The leading psychiatry deals by value
- Most active psychiatry licensing dealmakers
In Psychiatry Collaboration and Licensing Deals, the available deals are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
Psychiatry Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Chapter 1 - Introduction
Chapter 2 - Trends in psychiatry dealmaking
Chapter 3 - Financial deal terms for psychiatry partnering
Chapter 4 - Leading psychiatry deals and dealmakers
Chapter 5 - Psychiatry contract document directory
Chapter 6 - Psychiatry dealmaking by therapeutic target
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3Z
- Abbvie
- Ab Initio
- ABL Bio
- ABVC BioPharma
- Acer Therapeutics
- Ache
- AC Immune
- Actigraph
- Aculys Pharma
- Acumen Pharmaceuticals
- AcuraStem
- Adare Pharma Solutions
- Addex Therapeutics
- AffaMed Therapeutics
- AgeX Therapeutics
- AiBtl BioPharma
- AiCure
- Aiforia Technologies
- AI Longevity
- AimedBio
- Aitia
- Aker BioMarine
- Akili Interactive Labs
- Akome Biotech
- Albert Einstein College of Medicine
- Alchemab
- Alector
- Alex Therapeutics
- Algernon Pharmaceuticals
- Alkermes
- Allied Corp
- Alligator Bioscience
- Alnylam Pharmaceuticals
- Alpha Cognition
- Altasciences
- Alterity Therapeutics
- Alternative Solutions
- Altoida
- Alto Neuroscience
- Alvogen
- Alzamend Neuro
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Alzheimer's Foundation of America
- Alzheon
- AlzProtect
- Amerigen Pharmaceuticals
- Amydis
- ANANDA Scientific
- Anavex Life Sciences
- Ancora Bio
- Annovis Bio
- Apollo Health
- APRINOIA Therapeutics
- Aptamer Therapeutics
- AptarGroup
- Aptinyx
- Aquinnah Pharmaceuticals
- Arbormentis
- Arcade Therapeutics
- Arctic Therapeutics
- Ariana Pharma
- AriBio
- Ashvattha Therapeutics
- Astex Pharmaceuticals
- ATAI Life Sciences
- Atalanta Therapeutics
- Athira Pharma
- Attralus
- Autism Impact Fund
- Autism Learning Partners
- Avance Clinical
- Avicanna
- AxoSim
- Axsome Therapeutics
- Aytu BioPharma
- Banner Alzheimer's Institute
- Barrow Neurological Institute
- Baszucki Brain Research Fund
- Battelle Memorial Institute
- Bayer
- Baylor College of Medicine
- BC Neuroimmunology
- Beacon Biosignals
- Beckley Psytech
- Beckman Coulter
- BehaVR
- Beth Israel Deaconess Medical Center
- BetterLife Pharma
- Bicycle Therapeutics
- BioArctic Neuroscience
- biOasis Technologies
- Biodextris
- Biogen
- Biogenysis
- Biohaven Pharmaceuticals
- BioMed X Innovation Center
- BioPep
- Bioprojet
- bioRASI
- BioScript Solutions
- Biotx.ai
- Bird Foundation
- Blum Center for Health
- Boehringer Ingelheim
- Bolden Therapeutics
- Boston University
- Brain & Behavior Research Foundation
- Brain Balance Achievement Centers
- Brain Scientific
- Braxia Scientific
- Breakthrough Discoveries for Thriving with Bipolar Disorders Foundation
- Breath of Life International
- Bredis Healthcare
- Brigham and Women's Hospital
- Bristol-Myers Squibb
- Broad Institute
- Burke Neurological Institute
- C2N Diagnostics
- C4 Therapeutics
- Cadent
- Cala Health
- Cambridge Brain Sciences
- Cambridge Cognition
- Camino Pharma
- Canadian Armed Forces
- Canadian Institutes of Health Research
- Canary Speech
- Cantex Pharmaceuticals
- Cardiff University
- Carnegie Mellon University
- Cassava Sciences
- Catalent
- CB2 Insights
- CB Therapeutics
- Cedar Clinical Research
- Celgene
- Centene
- Centessa Pharmaceuticals
- Centre for Addiction and Mental Health
- Cerebral
- Cerevance
- Cerevel Therapeutics
- Cerveau Technologies
- Charite Universitatsmedizin Berlin
- Charles River Laboratories
- Charlotte's Web
- Chattanooga Center for Neurologic Research
- Children's Hospital of Philadelphia
- Cingulate
- Circular Genomics
- Citrine Medicine
- City of Hope
- CKD Bio
- Clalit Health Services
- Clario
- Clearmind Medicine
- Cleveland Clinic
- Clexio
- Click Therapeutics
- Clinilabs
- CND Life Sciences
- Cognition Therapeutics
- Cognito Therapeutics
- Cognoa
- CogState
- Columbia University
- Combat Stress
- Commave Therapeutics
- COMPASS Pathways
- Complutense University of Madrid
- ConSynance Therapeutics
- Core One Labs
- Cortechs.ai
- Covar Pharmaceuticals
- Coya Therapeutics
- CTD Holdings
- Curebase
- Cure Genetics
- Cure Network Dolby Acceleration Partners
- CURE Pharmaceutical
- Cybin
- Cyclerion Therapeutics
- Cyclo Therapeutics
- Cytox
- Daiichi Sankyo
- Dalriada Drug Discovery
- Data Tecnica International
- Deakin University
- Deep Cube
- Dementia Discovery Fund
- Dementia Research Institute
- Denali Therapeutics
- Denovo Biopharma
- Department of Defense
- Department of Veterans Affairs
- Develco Pharma
- Diadem
- DiagnaMed
- DiamiR
- Diamond Therapeutics
- Digestome Therapeutics
- Digital Medicine Society
- DTx Pharma
- Eagle Pharmaceuticals
- EIP Pharma
- Eisai
- Eli Lilly
- Elite Pharmaceuticals
- Endotherm
- Enigma Biomedical
- Enosis Therapeutics
- Enterin
- Enveric Biosciences
- ERP Biomarker Qualification Consortium
- Essential Pharmaceuticals
- Estee Lauder
- Esteve
- Eureka Eurostars
- Eurofarma
- European Wellness Biomedical Group
- EverInsight Therapeutics
- Eversana
- Evotec
- Exeltis
- Expansion Therapeutics
- Expesicor
- ExScientia
- Feinstein Institute for Medical Research
- Field
- Filament Health
- FINGERS Brain Health Institute
- Firefly Neuroscience
- Florida Atlantic University Research
- Fluence
- Forian
- Four H
- Frametact
- Freespira
- Frontage Clinical Services
- FSD Pharma
- Fujirebio Diagnostics
- Fuzionaire Diagnostics
- GABA Therapeutics
- Gaia
- Gain Therapeutics
- Gate Neurosciences
- Gedeon Richter
- Geisinger Health System
- Genentech
- General Genomics
- Genetika+
- GeNeuro
- Geneva University Hospitals
- Gentex
- Georgetown University
- GL Brands
- Glimpse Group
- Global Alzheimer's Platform (GAP)
- Global Down Syndrome Foundation
- GN Group
- GNS Healthcare
- Golden Meditech
- Goldfinch Bio
- Government of South Korea
- Graviton Bioscience
- Gray Matter
- GrayMatters Health
- Green Valley Pharmaceutical
- GSK
- GTx
- Gurnet Point Capital
- Hackensack Meridian Health
- Halberd
- Halia Therapeutics
- Halozyme Therapeutics
- Halucenex Life Sciences
- Hangzhou Highlightll Pharmaceutical
- Hapbee Technologies
- Happify Health
- Harmony Biosciences
- Harvard College
- Harvard Medical School
- Harvard University
- Healis Therapeutics
- Hebrew University of Jerusalem
- Helsinki University Central Hospital (HUCH) Comprehensive Cancer Center
- Herophilus
- Hesperos
- HLS Therapeutics
- HMNC Brain Health
- Hollister Biosciences
- Holmusk
- Hong Kong Baptist University
- Horizon Europe
- Hoth Therapeutics
- HP
- Hummingbird Diagnostics
- Hyloris Pharmaceuticals
- Hypersomnia Foundation
- I-mab
- IAMA Therapeutics
- Icahn School of Medicine at Mount Sinai
- Idorsia
- Imeka
- Impax Laboratories
- Impression Healthcare
- Inagene Diagnostics
- Incannex Healthcare
- Indegene Lifesystems
- Inexia
- Infineon
- Infinity BiologiX
- InformedDNA
- iNGENu
- INmune Bio
- Innosuisse
- Innovate UK
- Inscopix
- InSightec
- Insilico Medicine
- Insitro
- Institute for Molecular Medicine
- Institute for Research in Biomedicine
- Institute of Organic Chemistry and Biochemistry
- Integrated Micro-Chromatography Systems
- IntelGenx
- Intellipharmaceutics
- International Flavors and Fragrances
- Inventia Healthcare
- Inventum Genetics
- inviCRO
- Invo Healthcare
- Ionian University
- Ionis Pharmaceuticals
- IsoPlexis
- Italfarmaco
- Itamar Medical
- iX Biopharma
- IXICO
- JADBio
- Jaguar Health
- Janssen Biotech
- Janssen Pharmaceuticals
- Janssen Pharmaceutica NV
- Japan Tobacco
- Jazz Pharmaceuticals
- JelikaLite
- Jiangsu NHWA Pharmaceutical
- Johns Hopkins University
- Jolly Good
- Juvenile Bipolar Research Foundation
- Karuna Therapeutics
- Keio Gijuku University
- Kelai Pharmaceuticals
- KemPharm
- Ketabon
- Ketamine Infusions Centers of Texas
- KeyWise
- KGK Science
- Khalpey AI Lab
- Kindeva Drug Delivery
- Kings College London
- KT Corporation
- KYE Pharmaceuticals
- L-3 Communications
- Laboratorios Bago
- LANGaware
- La Paz Hospital
- Leidos
- LEXEO Therapeutics
- Libra International
- Lieber Institute
- Liechti Lab
- Lighthouse Pharmaceuticals
- Limbix
- Linical
- Litesprite
- LivaNova
- Livzon Pharmaceutical
- Longeveron
- Lotus Pharmaceuticals
- Lovell Government Services
- LTS Lohmann Therapie-Systeme
- Luca Healthcare
- LUCID
- Lundbeck
- Luxna Biotech
- Luye Pharma Group
- Maastricht University
- Magellan Healthcare
- Magic Leap
- Marinus Pharmaceuticals
- Marubeni
- Massachusetts General Hospital
- Mayo Clinic
- McGill University
- McLean Hospital
- McMaster University
- McQuade Center for Strategic Research and Development
- MedBridge
- Medical Food Solutions Research
- Medical University South Carolina
- Medicines Discovery Catapult
- MediPharm Labs
- Medison Pharma
- Medomie Pharma
- MedPharm
- Meilleur Technologies
- Merck and Co
- Meru Health
- Metabolon
- Michael J Fox Foundation
- Michigan State University
- Microsoft
- Milagro Pharmaceuticals
- Milken Institute Center for Public Health
- Mind Cure Health
- Mind Medicine
- Mindset Pharma
- MindShift Compounds
- Mira Pharmaceuticals
- Mitacs
- MitoCanada Foundation
- Mitochondrial Innovation Initiative
- MitoSense
- Mitsubishi Tanabe Pharma
- MMS
- Mochida Pharmaceutical
- Moleculera Labs
- Monash University
- Montefiore Health System
- Montreal Heart Institute
- Montreal Neurological Institute-Hospital
- Morgan Stanley
- Morris Animal Foundation
- Mosanna Therapeutics
- MSN Laboratories
- MSN Pharmaceuticals
- Multidisciplinary Association for Psychedelics Studies
- MyClearStep
- Mydecine Group
- MYND Life Sciences
- Myung In Pharm
- Naason Science
- Nacuity Pharmaceuticals
- National Disease Research Interchange
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of General Medical Sciences
- National Institute of Health Research
- National Institute of Mental Health
- National Institute on Aging
- National Institute on Drug Abuse (NIDA)
- National Institutes of Health
- Navidea Biopharmaceuticals
- Navitor Pharmaceuticals
- NeonMind Biosciences
- NervGen Pharma
- NeuCyte
- Neumora Therapeutics
- Neuraxpharm
- Neurimmune Therapeutics
- Neuro Bio
- Neurocrine Biosciences
- NeuroFront
- NeuroLex Laboratories
- Neurolief
- Neurolixis
- NeuroLucent
- Neuronetrix
- NeuroNexus
- Neuronic
- NeuroSense Therapeutics
- NeuroSigma
- Neurotrack
- NeuroTracker
- Neurotrope BioScience
- Neurovation Labs
- Newly Institute
- New York Presbyterian/Columbia
- NLS Pharmaceutics
- NOCD
- Noema Pharma
- Northwestern University
- Novartis
- Novoron Bioscience
- NRx Pharmaceuticals
- Nucro Technics
- Numerate
- Nurosene
- NYU Grossman School of Medicine for Preclinical and Clinical Research
- Oligomerix
- One Mind for Research
- Onera Health
- Ono Pharmaceutical
- Optina Diagnostics
- OptiNose
- Orexia Therapeutics
- Orexo
- Orion
- Orionis Biosciences
- Oryzon
- Ossianix
- Othair Prothena
- Otsuka
- Ottawa Hospital Research Institute
- Ovid Therapeutics
- OWP Pharmaceuticals
- Parexel
- Parkinson's UK
- Pasithea Therapeutics
- Passage Bio
- Patient-Centered Outcomes Research Institute
- PaxMedica
- PEAR Therapeutics
- Pediatrix Therapeutics
- Perception Neuroscience
- Pfizer
- PGI Drug Discovery
- Pharmanovia
- PharmaTher
- Pharmidex
- Pierre Fabre
- PINC AI Applied Sciences
- PoloMar Health
- PostEra
- Praetego
- Prasco Laboratories
- Predictmedix
- Pritzker Group
- Prometheus Laboratories
- ProMIS Neurosciences
- Prothena
- Protxx
- Providence
- Psilera
- Psycheceutical Bioscience
- Psychedelic Society Belgium
- PsychoGenics
- Psylo
- Pulvinar Neuro
- PureTech Health
- Purina
- PurMinds NeuroPharma
- QuantalX Neuroscience
- Quanterix
- Quest Diagnostics
- Quince Therapeutics
- Radboud University Nijmegen
- Rainwater Charitable Foundation
- RARE-X
- Readout Health
- Regenerative Medicine of Latin America
- Regenxbio
- Relmada Therapeutics
- Reputable Health
- Reset Pharmaceuticals
- RespireRx Pharmaceuticals
- RetiSpec
- RetroBrain
- Reverie Labs
- Revitalist Lifestyle and Wellness
- Revive Therapeutics
- Ro
- Roche
- Rockefeller University
- RogCon Biosciences
- Rosalind Franklin University of Medical Sciences
- Royalty Pharma
- Rugen Therapeutics
- Rx.Health
- SABI Mind
- Sage Bionetworks
- Sage Therapeutics
- Samsung Biologics
- Sanford Burnham Institute
- Sanford Health
- Sangamo Therapeutics
- Saniona
- Sanofi
- Sansero Life Sciences
- Santa Clara University
- Sawai Pharmaceuticals
- Schenker Technologies
- Schrodinger
- Science 37
- SciNeuro Pharmaceuticals
- SciSparc
- Scripps Research Institute
- Seelos Therapeutics
- Selonterra
- Sentia Medical Sciences
- Seqster
- Sequentify
- Shanghai Ark Biopharmaceutical
- Shape Therapeutics
- Shionogi
- Shionogi Pharma
- Siemens Healthineers
- Silo Pharma
- SilverCloud Health
- Sirion Biotech
- Skyhawk Therapeutics
- Sleep Consortium
- Sleepiz
- SleepScore Labs
- SoftBank
- Sosei
- Sosei Heptares
- Southwest College of Naturopathic Medicine & Health Sciences
- Spark Biomedical
- Sphere Health
- Spinogenix
- SpringWorks Therapeutics
- STADA Arzneimittel
- Stalicla
- Stanford University
- Stanford University School of Medicine
- Stem of Hope
- Stratus Research Labs
- St Vincent’s Institute of Medical Research
- SUDA Pharmaceuticals
- Sumitomo Dainippon Pharma
- Sumitomo Pharmaceuticals
- Sunovion Pharmaceuticals
- Sunstone Therapies
- Supernus Pharmaceuticals
- Swinburne University
- Sylics Contract Research
- Synaffix
- Syneos Health
- Synova Healthcare
- Sysmex
- T3D Therapeutics
- Tabula Rasa HealthCare
- Tactical Relief
- Taisho Pharmaceutical
- Takeda Pharmaceutical
- TALi
- Taliaz
- Technology University Dresden
- Teijin
- Terran Biosciences
- Teva Pharmaceutical Industries
- Therapeutic Solutions International
- TMS NeuroHealth Centers
- TONIX Pharmaceuticals
- Toronto Centre for Psychedelic Science
- Total Brain
- Towa Pharmaceutical
- Transcend Therapeutics
- TrialSpark
- Tridiuum
- Tris Pharma
- TruGenomix
- Tryp Therapeutics
- Tymora Analytical Operations
- UCB
- University Health Network
- University of Barcelona
- University of British Columbia
- University of Calgary
- University of California
- Davis
- University of California
- San Diego
- University of California Berkeley
- University of California Irvine
- University of California Los Angeles
- University of California San Francisco
- University of Colorado
- University of East London
- University of Florida
- University of Guelph
- University of Iowa
- University of Lethbridge
- University of Marburg
- University of Maryland Baltimore
- University of Miami
- University of Michigan
- University of Mississippi
- University of Missouri
- University of Nebraska
- University of North Carolina
- University of Oslo
- University of Oxford
- University of Pennsylvania
- University of Pittsburgh
- University of Saskatchewan
- University of Southern California
- University of Texas
- University of Texas Health Science Center at Houston
- University of Toronto
- University of Washington
- University of Wisconsin
- Uppsala University
- US Air Force
- UWM Research Foundation
- Vaccinex
- Vanda Pharmaceuticals
- Vanderbilt University
- Vandria
- Vaxxinity
- Vect-Horus
- Vektor Pharma
- Veltmeyer MD
- VeraSci
- Veravas
- Verge Genomics
- Verily
- Vibrent Health
- ViewMind
- Viome
- Virginia Commonwealth University
- Visiopharm
- VistaGen Therapeutics
- VitalHub
- Vitro Biopharma
- Vivos Therapeutics
- VoxNeuro
- Walgreens
- Washington University in St Louis
- Weill Cornell Medical College
- Willow Biosciences
- WinterLight Labs
- Wise Therapeutics
- Worldwide Clinical Trials
- Wren Therapeutics
- Xenon Pharmaceuticals
- XRHealth
- Yale School of Medicine
- Yale University
- Yamo Pharmaceuticals
- Yeda Research and Development Company
- Yissum Research Development
- Young Blood Institute
- Yumanity Therapeutics
- ZAI Laboratory
- Zambon
- Zelira Therapeutics
- Zevra Therapeutics
- Zhittya Genesis Medicine
- Zhongze Therapeutics
- ZYUS Life Sciences
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
